Pipeline Therapeutics

10578 Science Center Drive
Suite 200
San Diego
California
92121
United States

Tel: 8583497880

Email: info@pipeline-tx.com

Show jobs for this employer

15 articles with Pipeline Therapeutics

  • Pipeline Therapeutics today announced that Scott Oross has been appointed as General Counsel.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the initiation of a Phase 1 study of PIPE-307, a selective antagonist of the muscarinic M1 receptor, in up to 72 healthy volunteers.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the closing of an $80 million Series C financing.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in December. 2020 RBC Capital Markets Healthcare Private Company Conference Format: Analyst-Led Fireside Chat Date: Tuesday, December 15, 2020 Time: 9:20 a.m. ET / 6:20 a.m. PT

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will participate in a fireside chat and investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference, a fully virtual management access conference, taking place December 1-3.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, at 2:00 p.m. ET / 11:00 a.m. PT. About Pipeline Therapeutics Pipeline Therapeutics is a biopha

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Peter Slover as the company’s Chief Financial Officer.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Fall Private Company Showcase 2020, co-hosted by BMO, a fully virtual management access conference, on Thursday, October 15, at 1:40 p.m. ET / 10:40 a.m. PT.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the company’s Board of Directors. Ms. Lyons-Williams brings more than 20 years of executive and operational experience to Pipeline. “I am thrilled that Lori will be joining the Pipeline board as an indepe

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in September.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in three upcoming investor conferences in August. LifeSci Partners Private Company Virtual Summer Symposium Company Presentation Date: Tuesday, August 4, 2020 Time: 3:30 p.m. ET / 12:30 p.m. PT Piper Sandler Sum

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the initiation of a Phase 1/2a trial of the company’s lead product candidate, PIPE-505, a small molecule gamma secretase inhibitor (GSI), in sensorineural hearing loss (SNHL) associated with hearing speech in noisy environments.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Thu, Jun 4, 2020 at 3:00 p.m. ET.

  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.